Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

Abstract

Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4–1.0, 14.7, 0.1–0.3, 0.9–1.9, 1.0–2.0, 5, 4.4–8.6 and 0.5–1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60–70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.